FDA Approves Less Frequent Lebrikizumab Dosing Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis. By Kathryn Wighton June 10, 2026 2 min Conexiant Share Summary Takeaways Listen Insight Report Poll Top Institutions
